Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Retatrutide
Clinical
Research chemical
Summary
Investigational triple agonist (GLP-1/GIP/glucagon) with very high weight-loss results in mid-stage trials.
Categories
Metabolic & Body Comp
Mechanism
Simultaneous agonism at GLP-1, GIP, and glucagon receptors — combining appetite suppression with potential energy-expenditure effects via glucagon pathways.
Half-life
Long-acting; weekly-style clinical regimens under study
Routes
Subcutaneous injection
Legal / access
Not FDA-approved as of the last major development updates for general use; investigational status. Market research products are unregulated.
Key risks
- GI effects similar to incretins
- Heart-rate increases reported in trials
- Unknown long-term profile
Common claims
- Next-gen weight loss beyond dual agonists
- Dramatic recomp anecdotes from early access claims
Select peptide B